Patricia Marinello PharmD

Patricia Marinello, PharmD, is Executive Director, Oncology Clinical Research, at Merck, where she leads the Keytruda (pembrolizumab; anti PD-1) development team for Multiple Myeloma. Prior to her current role, Dr Marinello was Director of late development Oncology Clinical Research at Bristol-Myers Squibb (BMS) where she developed the EMPLICITI (Elotuzumab, anti-CS1) monoclonal antibody in multiple myeloma and was the Medical Lead for the development of Portrazza (Necitumumab, anti-EGFR) monoclonal antibody in lung cancer. Before BMS, Dr Marinello was a Director of clinical development at the Center of Molecular Immunology (CIM), a biotechnology company, which develops different modalities of immunotherapy for the treatment of cancer and infectious disease. Dr Marinello obtained her Doctor in Pharmacy degree from the University of Havana, where she earned an additional Masters degree in Experimental Immuno-Pharmacology.